Bayesian approaches to joint longitudinal and survival models accommodating both zero and nonzero cure fractions

Statistica Sinica

Volumn 17, Issue 2, 2007, Pages 445-462

  Chi, Yueh Yun ^a   Ibrahim, Joseph G ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

Breast cancer clinical trial; Cure rate model; Random effects

Indexed keywords

EID: 34547502683     PISSN: 10170405     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Berkson, J. and Gage, R. P. (1952). Survival curve for cancer patients following treatment. J. Amer. Statist. Assoc. 47, 501-515.
2. Brown E. R. and Ibrahim, J. G. (2003). Bayesian approaches to joint cure-rate and longitudinal models with applications to cancer vaccine trials. Biometrics 59, 686-693.
3. Chen, M. H. and Shao, Q. M. (1999). Monte carlo estimation of Bayesian credible and HPD intervals. J. Comput. Graph. Statist. 8, 69-92.
4. Gelfand, A. E., Sahu, S. K. and Carlin, B. P. (1996). Efficient parametrizations for generalized linear mixed models. Bayesian Statist. 5, 165-180.
5. Gelman, A. and Rubin, D. B. (1992). Inference from iterative simulation using multiple sequences. Statist. Sci. 7, 457-551.
6. Gilks, W. R. Best, N. G. and Tan, K. C. C. (1995). Adaptive rejection Metropolis sampling within Gibbs sampling. Appl. Statist. 44, 455-472.
7. Gilks, W. R. and Wild, P. (1992). Adaptive rejection sampling for Gibbs sampling. Appl. Statist. 41, 337-348.
8. Hurny, C., Bernhard, J., Coates, A. S., Castiglione M., Peterson, H. F., Gelber, R. D., Forbes, J. F., Rudenstam, C. M., Simoncini, E., Crivellari, D., Goldhirsch, A. and Senn, H. J. (2000). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347, 1279-1284.
9. Ibrahim, J. G., Chen, M. H. and Sinha, D. (2001). Bayesian Survival Analysis. Springer-Verlag, New York.
10. Ibrahim, J. G., Chen, M. H. and Sinha, D. (2004). Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine studies. Statist. Sinica 14, 863-883.
11. Law, N. J., Taylor, J. M. G. and Sandler, H. M. (2002). The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. Biostatistics 3, 547-63.
12. Song, X., Davidian, M. and Tsiatis, A. A. (2002). An estimator for the proportional hazards model with multiple longitudinal covariates measured with errors. Biostatistics 3, 511-28.
13. Spiegelhalter, D. J., Best, N. G., Carlin, B. P. and Van der Linde, A. (2002). Bayesian measures of model complexity and fit. J. Roy. Statist. Soe. Ser. B 64, 583-616.
14. The International Breast Cancer Study Group (1996). Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J. Clinical Oncology 14, 1885-1894.
15. Tsiatis, A. A. and Davidian, M. (2004). Joint modeling of longitudinal and time-to-event data: an overview. Statist. Sinica 14, 793-818.
16. Xu, J. and Zeger, S. L. (2001). The evaluation of multiple surrogate endpoints. Biometrics 57, 81-87.
17. Yakovlev, A. Y. and Tsodikov, A. D. (1996). Stochastic Models for Tumor Latency and their Biostatistical Applications. World Scientific, New Jersey.
18. Yu, M., Law, N. J., Taylor, J. M. G. and Sandler, H. M. (2004). Joint longitudinal-survival-cure models and their applications to prostate cancer. Statist. Sinica 14, 835-862.